Efficacy of oral Cynara scolymus and Silybum marianum on toxicity of imidocarb dipropionate in horses

Fernando Mosquera Jaramillo, Diego Darley Velasquez Piñeros, Rodrigo Romero Corrêa, Fabio Celidonio Pogliani, Bruno Cogliati, Raquel Yvonne Arantes Baccarin

ABSTRACT

Background Despite hepatotoxic effects, imidocarb dipropionate is the drug of choice for treatment of equine piroplasmosis. It is important, therefore, to identify adjuvant therapies that may improve the safety of imidocarb dipropionate by reducing the risk of liver damage during its use. The aim of the present study was to evaluate the hepatoprotective and hepatoregulatory effects of treatment with Cynara scolymus and Silybum marianum during administration of imidocarb dipropionate.

Methods Ten healthy horses, seroconverted to Theileria equi by C-ELISA, were treated with 5 mg/kg/day of imidocarb dipropionate for three consecutive days. The study population was divided into two groups. The control group did not receive any complementary treatments. The treated group received a daily oral supplement containing C scolymus and S marianum for 30 days. Physical, haematological and histological examinations of hepatic fragments were performed.

Results All haematological values remained within normal range for the study population. Histological analysis revealed that treated group animals had 62 per cent less lobular inflammation, 65 per cent less steatosis and 57 per cent less portal inflammation than control group animals, with an equivalent percentage of hydropic degeneration.

Conclusion C scolymus and S marianum supplements resulted in beneficial hepatoprotective effects in horses treated with imidocarb dipropionate.

INTRODUCTION

Piroplasmosis, one of the main parasitic diseases that affects horses, can be found in South and Central America, the Caribbean, Africa, Southern and Eastern Europe, and the Middle East. Only the USA, Canada, Australia, Japan and Iceland are not considered endemic areas. It is a tick-borne disease caused by the haemoprotezoan parasites Theileria equi (formerly called Babesia equi) and Babesia caballi. More than 90 per cent of the world’s total equine population is considered to live in regions infected with T equi, underscoring the power of this disease agent’s transmission system and the abundance of its vectors.

Equine piroplasmosis, which is also known in the literature as equine babesiosis, theileriosis (concerning T equi) and biliary fever affects all equid species, including donkeys, mules and zebras. Affected animals may have intermittent febrile spikes, anorexia, anaemia due to haemolysis, yellow mucous membranes with or without petechiae, limb oedema, abdominal discomfort, decreased athletic performance and even death. In addition to these serious health consequences, there are also important economic implications of the disease, including the high cost of treatment, high morbidity and restrictions on export of animals or participation in international equestrian events in disease-free countries.

Of the drugs most commonly used for the treatment of equine piroplasmosis, imidocarb dipropionate is considered to be the safest and most effective. According to the US Department of Agriculture’s Animal and Plant Health Inspection Service, treatment for piroplasmosis in horses must be performed with high doses of imidocarb dipropionate in order to ensure permanent elimination of the parasite from domestic animals. There is no doubt, however, that this drug has the potential for serious toxicity, especially in animals that have received multiple and consecutive treatments. In general, the toxic effects related to imidocarb dipropionate are directly related to the wide and effective tissue distribution of the drug, the prolonged period required until its complete elimination, and the accumulation of the drug in vascular and extravascular compartments.

Concurrently, the therapeutic use of medicinal plants has become widely accepted by the general public. The medical community has also begun supporting the uses of these agents, especially as their biological activities are being investigated more scientifically, proving both efficacy and safety.
Considering the great diversity of constituents present in these medicinal plants, they carry great potential as a natural source of pharmacotherapies and prototypical molecules. It is important to note, however, that some medicinal plants used in herbal preparations require thorough quality control, as they may contain variable chemical compositions or even toxic substances.10

*Cynara scolymus* L., commonly known as artichoke, is a medicinal plant that has beneficial effects on diseases of the bile ducts and liver. Artichoke leaves contain up to 2 per cent of phenolic acids, including caffeic acid, chlorogenic acid and cinnarin; flavonoids (0.1 per cent–1 per cent); and volatile oils.10 According to a meta-analysis by Salekzamani et al.,11 artichoke has health-promoting properties for a variety of diseases, with convincing evidence in animal models of its antioxidant ability to restore ‘redox homeostasis’. Unfortunately, the authors of that meta-analysis were unable to suggest the best dosage or duration of treatment for artichoke due to the high heterogeneity between included studies and the equivalent antioxidant effects identified with lower (<1000 mg/kg) and higher dosages (≥1000 mg/kg).

In studies conducted in rats with hepatotoxicity induced by alpha-amanitin,12 carbon tetrachloride13–15 or paracetamol and, in mice with alcohol-induced acute liver damage,16,17 it was observed that supplementation with artichoke leaf extract caused a significant decrease in the concentration of malondialdehyde (MDA) and a significant improvement in the activity of antioxidant enzymes, including superoxide dismutase, glutathione peroxidase and catalase. In addition, improvements were noted in the histopathological features of hepatocytes.15 Using an artichoke leaf hydroalcoholic extract, El-Boshy et al.18 treated cadmium toxicity in rats and also observed a significant decrease in liver concentrations of MDA compared with a control group.

*Silybum marianum* L., also called milk thistle, is another medicinal plant that has been used for over 2000 years as a therapeutic herb to treat liver diseases. Silymarin is a standardised dry extract of milk thistle seeds containing mainly flavonolignans (about 70 per cent–80 per cent w/w), as well as polymeric and oxidised polyphenolic compounds, thus constituting a mixture of flavonoids.19 The main flavonolignans of silymarin are silybin, sildianine and silchristine.20,21

Experimental studies in animals have shown protective effects of silymarin for hepatotoxicity induced by paracetamol, radiation, iron overload and carbon tetrachloride. These hepatoprotective effects may occur due to inhibition of lipid peroxide formation, elimination of free radicals and modification of the physical properties of cell membranes.22

In patients with liver diseases, several studies have demonstrated beneficial effects of treatment with silymarin, including its promotion of protein synthesis and its anti-inflammatory, immunomodulatory, antifibrotic and antioxidant activities.19 Furthermore, silymarin has been shown to have regulatory actions on the permeability of the mitochondrial membrane and to increase cell membrane stability during xenobiotic injuries.23 Silymarin also prevents the absorption of toxins by hepatocytes,24 suggesting potential efficacy in the treatment of liver injuries induced by drugs or toxic substances. Schrieber et al.25 showed that the availability of silymarin and, consequently, its efficacy, varied with the type of liver disease. The systemic bioavailability of silymarin can be improved in a number of ways, including the addition of solubilising substances like vitamin E and phosphatidylcholine, micelle formation with bile salts, and, notably, self-emulsification, a drug-delivery system that uses a microemulsion to deliver hydrophobic drugs.26,27

The hepatotoxic effects of imidocarb dipropionate during treatment of horses with piroplasmosis are well established; therefore, it is important to identify adjuvant therapies that may reduce the rate of liver damage and increase the safety of this agent. Furthermore, the known hepatoprotective effects of *C. scolymus* and *S. marianum* suggest that these agents may be useful as an adjuvant treatment of liver diseases. The aim of the present study was to evaluate the hepatoprotective and hepatoregulatory effects associated with *C. scolymus* (artichoke) and *S. marianum* (milk thistle) in horses treated with imidocarb dipropionate.

**MATERIALS AND METHODS**

**Animals**

Ten healthy male and female Arabian cross horses with an average age of five years and weights ranging from 350 to 400 kg were used in this study. The horses were seroconverted to *T. equi* using the C-ELISA technique. The horses were included in the study if they showed weight loss, or poor performance and condition or peripheral oedema. Horses presenting sudden onset of clinical signs which could lead to death, or signs as fever, inappetence, malaise and colic followed by diarrhoea were excluded.

The horses were treated at the Teaching and Research Support Centre/School of Veterinary Medicine and Animal Science - University of São Paulo (CAEP/FMIZ-USP). They were kept in a paddock without contact with ticks. Each horse was fed a total of 1 kg of a pelleted concentrate, twice a day, in addition to mineral salt. Tifton hay and water were offered ad libitum.

The horses were evaluated by a general physical examination, including assessments of heart rate, respiratory rate, rectal temperature, capillary perfusion time, skin turgor, auscultation of intestinal motility and mucosal staining; haematological tests, including blood count; biochemical assessments of the liver and muscles; and ultrasound assessments of the liver in order to exclude indicators of liver disease.

C-ELISA was used to measure antibody production resulting from an immune response to the parasite. The cut-off point for this response corresponded to a 40 per cent inhibition in colour formation, measured by reading the absorbance in a plate reader. Tested...
sera that produced a 40 per cent inhibition percentage were considered positive and tested sera that produced a percentage of inhibition less than 40 per cent were considered negative.

Application of imidocarb dipropionate

In order to eliminate the parasite from the horses and to maintain the characteristics of conservative protocols routinely used in equine medical clinics, a dosage of 5 mg/kg/day intramuscularly of imidocarb dipropionate was used for three consecutive days. This dosage was fractionated into two 2.5 mg/kg subdoses, with an hour-long interval between them. The application was carried out on day 0 (D0), day 1 (D1) and day 2 (D2).

In animals that exhibited signs of parasympathetic hyperstimulation, including spasmodic colic or diarrhoea, scopalamine was administered intravenously at a dosage of 0.3 mg/kg.

Supplementation group

The animals were randomly assigned to two groups with five animals each. To avoid order effects for each group (control or treated), 10 cards were kept in an envelope, and for each horse, the card was drawn at the time of the start of supplementation to address concealment. The control group did not receive any supplements after the start of supplementation to address concealment. The treated group received supplementation with a commercial product containing artichoke and thistle extracts (Hepvet, Vetnil, Louveira, SP, Brazil). The commercial product contained the following elements per kilogram: artichoke extract (13 g/day) routinely used in equine medical clinics, a dosage of 5 mg/kg/day intramuscularly of imidocarb dipropionate was used for three consecutive days. This dosage was fractionated into two 2.5 mg/kg subdoses, with an hour-long interval between them. The application was carried out on day 0 (D0), day 1 (D1) and day 2 (D2).

In animals that exhibited signs of parasympathetic hyperstimulation, including spasmodic colic or diarrhoea, scopalamine was administered intravenously at a dosage of 0.3 mg/kg.

Haematological and biochemical evaluations

Venous blood samples (5 mL) from the animals were collected 3 days (D-3) and 1 day (D-1) prior to the first application of imidocarb dipropionate (D0), and 1 day (D1), 5 days (D5), 17 days (D17), 23 days (D23) and 30 days (D30) after the first application. The samples were stored in siliconised glass tubes containing 50 µl of EDTA K3 as an anticoagulant, as well as in a dry tube, and were placed on ice for further processing at the Multi-User Laboratory of Veterinary Clinical Analysis of the Faculty of Zootecnia and Food Engineer at USP.

Red blood cell and leucocyte counts, haemoglobin measurements, determinations of globular volume and haematometric indices, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC), as well as differential leucocyte counts, were carried out using an automatic haematology analyser (model BC 2800vet, Mindray, Shenzhen, Nanshan, China).

The following evaluations of liver and muscle functions were also performed: levels of total protein, albumin, aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), direct and indirect bilirubin and creatine kinase (CK) using an automatic biochemical analyser (Randox RX, Dublin, County Antrim, UK).

Liver biopsies

Liver samples were collected using a percutaneous liver biopsy technique with a 14 G x 11.4 cm x 20 mm biopsy needle (Pro-Mag Ultra, Rio de Janeiro, Brazil) 3 days before imidocarb dipropionate (D-3) application, 10 days after the third application of imidocarb dipropionate (D12), and at the end of the experiment (D30).

The procedure was carried out with animals in season in a containment trunk after a 12 hours water and food fast. A 20 x 25 cm area was delineated over the right 12th and 14th intercostal spaces, at the intersection of a line established from the coxal tuberosity to the midpoint between the elbow and the tip of the scapula. This area was subjected to trichotomy and antisepsis with iodised alcohol. The animals were sedated using 0.02 mg/kg of 1 per cent detomidine, intravenously. Local infiltrative anaesthesia was then performed with 5 ml of 2 per cent lidocaine hydrochloride without vasoconstrictors. The skin incision was made using ultrasound assistance, and then the sharp biopsy needle was introduced by piercing the intercostal muscles and reaching the liver. The needle introduction was also guided by ultrasound, thus preventing the perforation of intestinal loops. The needle was directed towards the opposite elbow and, also with the aid of ultrasound, the depth necessary for the penetration of the needle into the liver parenchyma was determined (figure 1).

Histopathological evaluation

Liver biopsy samples were immediately fixed in a 10 per cent formaldehyde solution for 24 hours and then stored in a 70 per cent alcohol solution. Subsequently, the samples were sent to the Histopathology Laboratory of the Department of Pathology/FMVZ-USP for histological processing and manufacturing of paraffin blocks. Finally, 5 µm histological sections were stained using haematoxylin-eosin (HE) for histopathological evaluation of the liver.

Histopathological changes were graded according to their intensity, and classified as mild, moderate, or intense. The following parameters were evaluated: presence of lobular inflammatory infiltrate, pigment...
accumulation, oedematous degeneration and portal inflammatory infiltrate.

Statistical analysis

Statistical Package for Social Science V.19.0 was used for data analysis. For quantitative variables, normal distribution of the data was assessed using the Shapiro-Wilk test. Variables without a normal distribution were subjected to numerical transformation by the inverse, as described by Templeton. Variables with normal distributions and those normalised by the inverse were submitted to the one-way test for analysis of variance over time, followed by the Bonferroni post hoc test for multiple comparisons between timepoints. The effect of time on variables with non-parametric distributions was assessed using the Friedman test, followed by the Wilcoxon post hoc test. For group comparisons within each timepoint, Student’s t test for independent samples was used. For analysis of qualitative variables, the association of variables with the experimental groups was performed within each moment using the Fisher test and the $\chi^2$ test. Fisher’s test was used when the variables were binary, whereas the $\chi^2$ test was used with variables that had more than two categories. For all tests, a P value of <0.05 was considered to be a significant result, with the trend >0.05 and<0.1.

RESULTS

C-ELISA

After study completion, another C-ELISA test was conducted on all animals to verify seronegativity for *T. equi*. Despite the use of 5 mg/kg of imidocarb dipropionate, a relatively high dose, only four animals became seronegative (table 1).

Physical examination

Four horses presented spasmodic colic and eight horses showed faeces softening on different days after 1 hour of the imidocarb dipropionate administration. All these horses were treated with scopolamine, and there was prompt remission of the clinical signs.

Heart rate, respiratory rate, rectal temperature, capillary perfusion time, skin turgor, auscultation of intestinal motility and mucosal colour did not change significantly in either group.

Haematological evaluations

The number of red blood cells, the concentration of haemoglobin and the levels of haematocrit and platelets did not differ significantly between the groups or between different timepoints observed in the same group (P>0.05) (figure 2). MCV values increased in the treated group in relation to baseline values (D-3) on D23 and, in the control group, on D5 (P<0.05). MCH values increased in the treated group in relation to the baseline values (D-3) on D30 and, in the CG, from D17 to D30 (P<0.05). MCHC values increased in the treated group in relation to baseline values on D30 and, in the CG, on D0, D5, D17 and D30 (P<0.05) (figure 2). The values of

| Animal | *T. equi* Day 3 | % inhibition at antibody level | *T. equi* Day 30 | % inhibition at antibody level |
|--------|----------------|-------------------------------|-----------------|-------------------------------|
| 1      | Positive       | 85                            | Positive       | 82                            |
| 2      | Positive       | 84                            | Positive       | 81                            |
| 3      | Positive       | 87                            | Positive       | 81                            |
| 4      | Positive       | 81                            | Positive       | 73                            |
| 5      | Positive       | 53                            | Negative       | 4                             |
| 6      | Positive       | 52                            | Negative       | 6                             |
| 7      | Positive       | 72                            | Positive       | 62                            |
| 8      | Positive       | 85                            | Positive       | 82                            |
| 9      | Positive       | 55                            | Negative       | 10                            |
| 10     | Positive       | 54                            | Negative       | 6                             |

Table 1 Seropositive and seronegative animals for *Theileria equi* at the beginning and after treatment with imidocarb dipropionate.
MCV, MCH and MCHC did not show statistical difference between the groups.

The number of leucocytes decreased in the treated group compared with the CG on D17 and D23 (P<0.05) (figure 3). There were no significant differences in the number of eosinophils, monocytes or lymphocytes in relation to baseline values in both groups or between the groups (P>0.05).

Biochemical evaluations

There were no significant differences in the total protein concentration in the two groups in relation to the baseline values (D-3). Albumin concentrations, however, decreased in the treated group in relation to baseline values from D0 to D30 and, in the CG, on D1, D5 and D30 (P<0.05). There were no significant differences between the groups (P>0.05) (figure 4).

The concentration of GGT in both groups did not differ from baseline (P>0.05); however, an increase in the concentration of GGT was observed in the treated group in relation to the control group on D30 (P<0.05). The concentrations of AST increased in the treated group in relation to the baseline value on D0 and D17 (P<0.05) and, in the control group, on D0 and D5 (P<0.05). An increase in GGT in the treated group was observed in relation to the control group on D5 and D23 (P>0.05) (figure 4). The CK concentration increased in the treated group on D0 in relation to baseline values (P<0.05) and, in the control group, on D0 and D1 (P<0.05). The concentrations of total, direct and indirect bilirubin did not change significantly between the observed timepoints in each group or between the groups (figure 5).

Histopathological evaluation

Liver fragments were evaluated for the presence of lobular inflammatory infiltrate, pigment accumulation, steatosis, hydropic degeneration and portal inflammatory infiltrate. These histopathological changes were graded according to intensity as mild, moderate or intense. Histological analysis showed that animals in the treated group had 62 per cent less lobular inflammation, 55 per cent less pigment accumulation, 65 per cent less steatosis, 57 per cent less portal inflammation and an equal percentage of oedematous degeneration compared with the control group (figure 6).

DISCUSSION

Imidocarb dipropionate is widely used in equine medicine as the drug of choice for control and prevention of infestation by the intraerythrocytic parasite, *T. equi*. The
toxic effects associated with imidocarb dipropionate are directly related to the wide and effective tissue distribution of the drug, the prolonged period required for its complete elimination, and the sequestration and accumulation of the drug in vascular and extravascular compartments. Considering these drug properties, this study aimed to evaluate whether a supplement containing C. scolymus and S. marianum could lead to a reduction in liver damage and an increase in safety during treatment of horses with imidocarb dipropionate. This was the first time that the use of these supplements has been studied in horses being treated with imidocarb dipropionate.

Of note, the animals did not exhibit any discomfort or changes in behaviour after using the formulation during the experimental period. The physiological constants also remained within normal limits throughout the treatment period.

Despite increased values for MCV, MCHC and MCH in both the treated group and control group in relation to baselines values, all values remained within the normal reference ranges for the equine species. Accordingly, the use of this formulation at the administered dosages did not affect the rheological function of the horses. Observed changes in these values may have been related to adequate control of the theileriosis, an effect that is expected after treatment with imidocarb dipropionate.

There was also an observed decrease in the number of leucocytes in the treated group at the end of the experiment compared with the control group; however, all values remained within the normal reference range for the species. The reduction of this parameter in the treated group may have been related to lower levels of liver inflammation, since it is known that silymarin has anti-inflammatory and immunomodulatory effects. GGT values remained stable in all biochemical analyses. Although most serum GGT activity occurs in the liver, this enzyme is also found in high concentrations in renal, intestinal, pancreatic and mammary gland diseases. The GGT enzyme has a half-life of approximately 3 days in horses and is mainly associated with the membranes of the biliary epithelium. It is considered to be an excellent test to detect liver disease in horses, with greater sensitivity for chronic disease. In the present study, the toxic effect of imidocarb dipropionate on the liver was considered to be acute, a feature that likely contributed to normal GGT concentrations.
injury may also have been responsible for the increase in both enzymes observed in this study.

The concentration of the GGT enzyme was higher in the treated group than in the control group on D5, and the concentration of AST was higher on D23 and D30 (P<0.05). When these two enzymes are concurrently increased, it strongly suggests liver damage. However, liver damage did not occur during this experiment, making it difficult to prove the origin of the increase in these enzymes. One possible alternative test would be the measurement of the enzyme sorbitol dehydrogenase (SDH), as it is specific for liver assessments and indicates leakage of the cytoplasmic contents of hepatocytes. In horses, SDH is present in high concentrations in the liver and in lower concentrations in other tissues, more specifically indicating hepatocellular damage than AST.

Unfortunately, the in vitro stability of this enzyme is much less than that of other liver enzymes, necessitating blood sample analysis within 5 hours after collection if stored at room temperature, or up to 48 hours if frozen. In the present study, the concentrations of total, direct and indirect bilirubin remained within the normal range of values for the species.

Histopathological examinations of liver fragments obtained by ultrasound-guided or laparoscopic-guided percutaneous biopsies are the best diagnostic and prognostic means of evaluating liver disease, with more sensitivity and specificity than the biochemical tests previously listed. In this study, histological assessments of liver samples showed an increase in portal inflammation in both groups in relation to the initial values, with lower levels of inflammation in the treated group compared with the control group on D12 (10 days after the third imidocarb dipropionate application). In the control group, lobular inflammation was also identified at different timepoints during the experiment; however, it was absent in the treated group after imidocarb dipropionate application (D12). This finding may have been observed at this timepoint because imidocarb dipropionate had reached maximum blood concentration levels, and this drug is known to cause direct damage to the hepatocytes, which results in inflammation and, eventually, in hydropic degeneration.

Hydropic degeneration cannot be identified without other concomitant histological lesions and is usually associated with inflammatory changes. In this study, hydropic degeneration was found in animals in both the treated group and the control group at 10 days after the application of imidocarb dipropionate (D12). This finding may have been observed at this timepoint because imidocarb dipropionate had reached maximum blood concentration levels, and this drug is known to cause direct damage to the hepatocytes, which results in inflammation and, eventually, in hydropic degeneration.

According to Hackett et al., portal inflammation and steatosis are the primary histopathological lesions of the liver identified in horses. Similar findings were observed in the present study. According to these authors, drugs with anti-inflammatory and antifibrotic properties would best facilitate hepatic metabolism and favour the regeneration of hepatocytes.

In the present study, it is inferred that the antioxidant and beta oxidation regulatory activities associated with C scolymus (artichoke) and S marianum (silymarin) resulted in effects that facilitated liver metabolism, contributing to the positive results observed in the treated group. Further studies using increasing dosages of these compounds are recommended for a more comprehensive evaluation.

CONCLUSION

It is concluded that the use of a supplement formulation containing C scolymus and S marianum resulted in beneficial hepatoprotective effects in horses receiving imidocarb dipropionate.
Contributors The experiment was conceptualised by FMJ, RRC and RYAB; methodology: FMJ, FCP, BC and RYAB; validation of data was performed by FCP, RRC and BC; formal analysis was done by FMJ and RYAB; investigation was done by FMJ, DDPV, FCP and RRC; resources were looked up by RRC and RYAB; curation and preparation, visualisation of data and writing—original draft preparation were performed by FCJ and RYAB; supervision and writing of the review was done by all coauthors; editing was done by FCJ and RYAB, the project was administered by FCJ and RYAB.

Funding This research was supported by the National Council for Scientific and Technological Development, Brasília, DF, Brazil, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil—Finance Code 001. These sponsors had no influence on the study design, data collection, analysis and interpretation, or on the writing of the manuscript and on the decision to submit for publication.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request (baccarin@usp.br).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Raquel Yvonne Arantes Baccarin http://orcid.org/0000-0001-9730-0840

REFERENCES
1. de Waaal DT. Equine piroplasmosis: a review. Br Vet J 1992;148:6–14.
2. Peixeira M de C. Efeitos do dipropionato de imidocarb sobre variáveis de desempenho, bioquímica sérica e hematologia em equinos puro sangue árabe portadores assintomáticos de Theileria equi. Universidade estadual paulista “Julio de Mesquita Filho”, 2011.
3. Ullenberg G, Babesia—a historical overview. Vet Parasitol 2006;138:3–10.
4. Thomassian A. Enfermidades DOS Cavalo. 4th ed. Livraria Varela. São Paulo: Varela, 2005: 295–300.
5. Belloli C, Cresczenio G, Lai O, et al. Pharmacokinetics of imidocarb dipropionate in horses after intramuscular administration. Equine Vet J 2002;34:625–9.
6. Cechinel Filho V, Yunes RA. Estratégias para a obtenção de compostos farmacologicamente ativos a partir de plantas medicinais: conceitos sobre modificação estrutural para otimização de compostos farmacologicamente ativos a partir de plantas medicinais. J Med Biol Res 2015;71 Suppl 1:S58–65.
7. Douglas Kinghorn A, Kinghorn AD. Pharmacognosy in the 21st century. J Pharm Pharmacol 2001;53:135–48.
8. Capasso R, Izzo AA, Pinto L, et al. Phytotherapy and quality of herbal medicines. Fito terapia 2000;71 Suppl 1:S58–65.
9. Efficacy CJB. Safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian J Med Biol Res 2000;33:179–89.
10. Guimarães E. Desenvolvimento E validação de metodologia analítica para o controle químico da qualidade de fitoterápicos a base de extrato seco de alcaçuz. Programa de Pós-Graduação em Vigilância Sanitária Instituto Nacional de Controle de Qualidade em Saúde Fundação Oswaldo Cruz, 2007.
11. Salekzamani S, Esbarami-Mameghani M, Rezzadadeh K. The antioxidant activity of artichoke (Cynara scolymus): a systematic review and meta-analysis of animal studies. Phytother Res 2019;33:55–71.
12. Kaymaz MB, Kandemir FM, Pamukçu E, et al. Effects of aqueous artichoke (Cynara scolymus) leaf extract on hepatic damage generated by Alpha-amanitine. Kafkas Univ Vet Fak Derg 2016;6.
13. Abdel-kader M, El-Sayed EM, Kassem SS, et al. Protective and antioxidant effects of Cynara scolymus leaves against carbon tetrachloride toxicity in rats. Pharm Biol Chem Sci 2014;5:1373–80.
14. Al-Ahmad MA. Protective effect of artichoke (Cynara scolymus L.) leaves and pulp extracts against carbon tetrachloride-induced acute hepatic toxicity in rats. World Appl Sci J 2014;32:1004–14.
15. Colak E, Ustuner MC, Tekin N, et al. The hepatoprotective effects of Cynara scolymus L. leaf extract on carbon tetrachloride-induced oxidative stress and hepatic injury in rats. Spring erplus 2016;5:1–9.
16. El-Morsy EM, Kamel R. Protective effect of artichoke leaf extract against paracetamol-induced hepatotoxicity in rats. Pharmacol Biochem Behav 2015;136:57–73.
17. Tang X, Wei R, Deng A, et al. Protective effects of ethanolic extracts from artichoke, an edible herbal medicine, against acute alcohol-induced liver injury in mice. Nutrients 2017;9:72.
18. El-Boshy M, Ashshi A, Gaith M, et al. Studies on the protective effect of the artichoke (Cynara scolymus) leaf extract against cadmium toxicity-induced oxidative stress, hepatorenal damage, and immunosuppressive and hematological disorders in rats. Environ Sci Pollut Res Int 2017;24:12372–83.
19. Abenavoli L, Izzo AA, Milic N, et al. Milk thistle (Silybum marianum): a Concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202–13.
20. Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008;15:9–20.
21. Sayyah M, Boostani H, Pakseresht S, et al. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive– Compulsive disorder. Prog Neuro Psychopharmacology Biol Psychiatry 2010;34:386–52.
22. Valenzuela A, Lagos C, Schmidt K, et al. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 1985;34:2209–12.
23. Servidio G, Bellamini E, Stanca E, et al. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic Biol Med 2014;73:117–26.
24. Trakulsrichai S, Snapha C, Tungpoo A, et al. Clinical characteristics and outcome of toxicity from Amanita mushroom poisoning. Int J Gastroenterol Hepatol 2017;10:395–400.
25. Schriever SJ, Hawke RL, Zen W, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos 2011;39:2182–90.
26. Yang G, Zhao Y, Feng N, et al. Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids. Asian J Pharm Sci 2015;10:194–202.
27. Silybin BM. A major bioactive component of milk thistle (Silybum marianum L Gaertn.) chemistry, bioavailabilility, and metabolism. Molecules 2017;22:11–1.
28. Correa R, Roncati N. Veterinária GB–AH, 2005. Uso da eficácia terapêutica do Dipropionato de imidocarb no tratamento da Piroplasmose equina. A Hora Veterinaria 2005;144:53–6.
29. De Medeiros MBA, De Souza FF, Nóbreza Neto PI, et al. Técnica de biópsia hepática guiada pelo ultrassom em bezerros. Rev Educ Contin Em Med Veterinária e Zootec do CRMV-SP 2002;5:94–9.
30. De QDJ. Alterações clínicas e laboratoriais de equinos submetidos biópsia hepática com agulha trucut guiada por ultrassom. Universidade Estadual Paulista- UNESP, 2014.
31. Templeton GF. A two-step approach for transforming continuous variables to normal: implications and recommendations for is research. Commun Assoc Inf Syst 2011;28:41–58.
32. Walton RM. Equine clinical pathology. Wiley Blackwell, 201: 279.
33. De QDJ. Dias DPM, Gravena K. Afecciones Hepáticas en Equinos. Investigação 2016;15:14–18.
34. Reed SM, Bayly WM, Sellon DC. Equine internal medicine. 4ed. Missouri: Elsevier, 2010: 1566.
35. Felício PRG. Métodos de diagnóstico de doença hepática em equinos. Universidade de Lisboa, 2018.
36. Thrall MA, Weiser G, Allison RW. Hematology E Bioquímica Clínica Veterinária. 2 ed. Rio de Janeiro: Guanabara Koogan, 2015: 349–60.
37. Dunkel B, Jones SA, Pinilla MJ, et al. Serum bile acid concentrations, histopathological features, and short-, and long-term responses in horses with hepatic disease. J Vet Intern Med 2015;29:644–50.
38. Davoudi SM, Eshtaghi M, EdalatiNasab M. Overview of hepatic disease in small animals. Adv Biore 2015;4:12–20.
39. Bergero D, Nery J. Hepatic diseases in horses. J Anim Physiol Anim Nutr 2008;90:345–55.
40. McGavin MD, Zachary JF, Bases D. Hepatology A Patologia em Veterinária. 4th ed. Rio de Janeiro: Elsevier, 2009: 1493.
41. De Lemos HPJ, De Lemos AAL. Alcachofra. Diagnóstico Trat 2012;17:59–61.
42. Hackett ES, Twedd DC, Gustafson DL, et al. Hepatic disease of horses in the Western United States. J Equine Vet Sci 2016;45:32–8.